[144] IBEX Ltd SEC Filing

Rhea-AI Filing Summary

IBEX Ltd filed a Form 144 notice disclosing a proposed sale of 5,000 shares of its common stock by an insider. The filing names Charles Schwab as the broker and lists an approximate sale date of 09/16/2025 on Nasdaq. The shares were acquired as stock grants on 12/31/2018 and paid via equity compensation. The filing also reports a recent sale of 295 shares on 07/01/2025 for $8,592. The filer affirms no undisclosed material adverse information.

Positive

• Disclosure of proposed sale of 5,000 common shares with broker and estimated sale date provided
• Acquisition details provided: shares were received as stock grants on 12/31/2018 and paid via equity compensation
• Recent prior sale disclosed: 295 shares sold on 07/01/2025 for $8,592, enhancing transparency

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider sale notice showing a planned disposal of 5,000 shares and a small prior sale; no new financial metrics disclosed.

The Form 144 is a regulatory disclosure of an insider's intent to sell shares, specifying broker, number of shares, acquisition date and nature (stock grants), and an estimated sale date. This filing provides transparency on insider liquidity but does not include operational or earnings data. The recent small sale of 295 shares and the planned 5,000-share sale are ordinary reporting events; absent additional context, they are not material to company fundamentals.

Corporate Governance Expert

TL;DR: Proper procedural filing indicating compliance with Rule 144; signer certifies no undisclosed material information.

The notice documents that the securities were granted on 12/31/2018 and that payment was equity compensation, aligning with common executive/employee award treatment. The attestation that no material nonpublic information exists is standard and required. This filing demonstrates compliance with disclosure requirements but does not signal governance changes or material corporate actions.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab Corp. 3000 Schwab Way Westlake TX 76262	5000	195001.00	13315077	09/16/2025	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/31/2018	Stock Grants	Issuer			22426	12/31/2018	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Julie Casteel 1717 Pennsylvania Avenue NW Suite 825 Washington DC 20006	295	07/01/2025	295	8592.00

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does IBEX's Form 144 announce?

The filing discloses a proposed sale of 5,000 common shares on or about 09/16/2025 with Charles Schwab listed as broker.

When and how were the shares being sold acquired?

The shares were acquired as stock grants on 12/31/2018 and the payment type is listed as equity compensation.

Has the filer sold any IBEX shares recently?

Yes. The filing reports a sale of 295 shares on 07/01/2025 generating $8,592.00 in gross proceeds.

On which exchange is the sale expected to occur?

The proposed sale is expected to be executed on Nasdaq.

Does the filer attest to possession of material nonpublic information?

The filer represents by signature that they do not know any material adverse information about the issuer that has not been publicly disclosed.